bluuebunny/crossref_metadata_2025 huggingface dataset:
Fig. S2 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
Authors: Inoue Akira , Mizushima Tsunekazu , Wu Xin , Okuzaki Daisuke , Kambara Nanami , Ishikawa Sho , Wang Jiaqi , Qian Yamin , Hirose Haruka , Yokoyama Yuhki , Ikeshima Ryo , Hiraki Masayuki , Miyoshi Norikatsu , Takahashi Hidekazu , Haraguchi Naotsugu , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S2. Screening for candidate target genes of MIRTX. (A) In silico whole genome sequence analysis demonstrated that 1043 genes possessed a putative binding site in the 3''-UTR of the mRNA for the seed sequence of MIRTX. (B) cDNA microarray data showed that 74 of the 1043 genes were significantly down-regulated (fold change < 0.67) at 48 h after transfection, in DLD1 cells that overexpressed MIRTX compared to negative control miRNA. DNA microarray analysis was performed as follows.; Gene expression analysis using the Whole Human Genome Microarray Kit, 4x44K v2 (G4845A) (Agilent) was performed as one-color experiments. Total RNA from transfected DLD1 cells was extracted using the miRNeasy kit (Qiagen) following the manufacturer''s instructions. A total of 200 ng of total RNA was reverse transcribed into double-stranded cDNAs using the Low Input Quick-Amp Labeling Kit (Agilent). After labeling of cRNAs with Cy3-CTP (Amersham Pharmacia Biotech), Purified Cy3-labeled cRNAs (1650 ng) were hybridized to the microarrays at 65 {degree sign}C for 17 h following the manufacturer''s protocol. After hybridization using a Gene Expression Hybridization Kit (Agilent), slides were washed in GE washing buffer and scanned with an Agilent Microarray Scanner G2505C following the manufacturer''s instructions. Feature extraction software (Version 10.7.3.1) was used to convert images into gene expression data. Raw data were imported into GeneSpring GX 11.0 (Agilent) for database management and quality control. Access to raw data concerning this study was submitted under GEO accession number GSE83634.
Supplementary Methods and Synthesis of RED-106 from CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
Authors: Drake Penelope M. , Carlson Adam , McFarland Jesse M. , Bañas Stefanie , Barfield Robyn M. , Zmolek Wesley , Kim Yun Cheol , Huang Betty C.B. , Kudirka Romas , Rabuka David
Published: April 2023

Supplementary Methods and Synthesis of RED-106
Figures S1-S11, Table S1 from CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
Authors: Drake Penelope M. , Carlson Adam , McFarland Jesse M. , Bañas Stefanie , Barfield Robyn M. , Zmolek Wesley , Kim Yun Cheol , Huang Betty C.B. , Kudirka Romas , Rabuka David
Published: April 2023

Fig S1. ELISA formats for detection of various analytes. Fig S2. Biophysical characterization of CAT-02-106. Fig S3. Competitive ELISA data showing CAT-02-106 binding to CD22. Fig S4. CAT-02-106 internalization on Ramos, Granta-519, and WSU-DLCL2 cells. Fig S5. CAT-02-106 in vitro cytotoxicity test on CD22-negative cells. Fig S6. The CAT-02-106-related ADC, anti-HER2 RED-106, does not induce bystander killing. Fig S7. Comparison of cell surface CD22 expression levels on Ramos and WSU-DLCL2 cells. Fig S8. Ramos and WSU-DLCL2 xenograft study data plotted as individual animals. Fig S9. Mouse body weights from Ramos and WSU-DLCL2 xenograft studies. Fig S10. CAT-02-106 binding to cynomolgus monkey B cells as assessed by flow cytometry. Fig S11. CAT-02-106 cross-reactivity to human and cynomolgus tissues. Table S1. Summary of pharmacokinetic findings in rats dosed at 3 mg/kg with CAT-02-106.
Figure S3 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Authors: Tsai Cheng-Yu , Sun Si , Zhang Hongying , Local Andrea , Su Yongxuan , Gross Larry A. , Rice William G. , Howell Stephen B.
Published: April 2023

Role of ABCG2 in resistance to Fe(253)3.
Figure S1 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Authors: Tsai Cheng-Yu , Sun Si , Zhang Hongying , Local Andrea , Su Yongxuan , Gross Larry A. , Rice William G. , Howell Stephen B.
Published: April 2023

Influx and efflux of APTO-253 and Fe(253)3.
Supplementary Materials and methods, Supplementary Figures S1-S8 from Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes
Authors: Payton Marc , Cheung Hung-Kam , Ninniri Maria Stefania S. , Marinaccio Christian , Wayne William C. , Hanestad Kelly , Crispino John D. , Juan Gloria , Coxon Angela
Published: April 2023

Supplementary Figure S1 shows the cellular effects of AKIs and anti-leukemic agents across a panel of human AML cell lines. Supplementary Figure S2 shows expression of aurora-A and aurora-B protein levels in four AML cell lines. Supplementary Figure S3 shows AMG 900 induces a dose-dependent increase in polyploidy, apoptosis, and p53 protein levels in MOLM-13 cells. Supplementary Figure S4 shows AMG 900 plus Ara-C combination matrix and CI determination in MOLM-13 cells. Supplementary Figure S5 shows AMG 900 induced apoptosis is attenuated by peptide inhibitors of caspases in MOLM-13 cells. Supplementary Figure S6 shows FC gating strategy for annexin-V coupled JC-1 assay. Supplementary Figure S7 shows the anti-proliferative effects of AMG 900 and AZD1152-hQPA on primary human bone marrow mononuclear cells in culture. Supplementary Figure S8 shows a moderate reduction in mouse body weight after AMG 900 treatment.
Supplementary Tables S1 to S10 from Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer
Authors: Nerlakanti Niveditha , Yao Jiqiang , Nguyen Duy T. , Patel Ami K. , Eroshkin Alexey M. , Lawrence Harshani R. , Ayaz Muhammad , Kuenzi Brent M. , Agarwal Neha , Chen Yunyun , Gunawan Steven , Karim Rezaul M. , Berndt Norbert , Puskas John , Magliocco Anthony M. , Coppola Domenico , Dhillon Jasreman , Zhang Jingsong , Shymalagovindarajan Subramaniam , Rix Uwe , Kim Youngchul , Perera Ranjan , Lawrence Nicholas J. , Schonbrunn Ernst , Mahajan Kiran
Published: April 2023

Supplementary Table 1: Table provides information on the siRNA sequences and/or chemical structures of the non-FDA approved inhibitors for bromodomain proteins, transcription factors and kinases described in the current study. Supplementary Table 2: Sequences of primers used for qRT-PCR analysis of various targets described in the study. Supplementary Table 3: Sequences of primers used for ChIP analysis of various targets described in the study. Supplementary Table 4: Analysis of HOXB13 target gene expression in the GSE92721 data set. Supplementary Table 5: Analysis of HOTBIN10 gene expression in the GSE92721data set. Supplementary Table 6: Analysis of HOTBIN10 gene expression in the Moffitt TCC data set. Supplementary Table 7: Clinical parameters of the primary cancers in the Moffitt TCC data set. Supplementary Table 8: Clinical parameters of the metastatic cancers in the Moffitt TCC data set. Supplementary Table 9: Analysis of HOTBIN10 genes in MSKCC gene expression data set (GSE21034). Supplementary Table 10: Analysis of HOTBIN10 gene expression in the GSE67980 CTC data set.
Supplementary Figures S1-S7 and Supplementary Methods from Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer
Authors: Nerlakanti Niveditha , Yao Jiqiang , Nguyen Duy T. , Patel Ami K. , Eroshkin Alexey M. , Lawrence Harshani R. , Ayaz Muhammad , Kuenzi Brent M. , Agarwal Neha , Chen Yunyun , Gunawan Steven , Karim Rezaul M. , Berndt Norbert , Puskas John , Magliocco Anthony M. , Coppola Domenico , Dhillon Jasreman , Zhang Jingsong , Shymalagovindarajan Subramaniam , Rix Uwe , Kim Youngchul , Perera Ranjan , Lawrence Nicholas J. , Schonbrunn Ernst , Mahajan Kiran
Published: April 2023

Supplementary Fig. 1. Epigenetic landscape and the transcription cofactor recruitment at the HOXB13 enhancer region under various treatments; Supplementary Figure 2. BRD4 is a target of the dual BET-kinase inhibitors in CRPCs; Supplementary Figure 3. Sensitivity of normal and AR negative cell lines to the novel BET-kinase inhibitors; Supplementary Figure 4. HOXB13 but not FOXA1 is under the epigenetic control of BRD4 in prostate cancer cells; Supplementary Figure S5. Haploinsufficiency of HOXB13 sensitizes CRPCs to the novel BET-kinase inhibitors; Supplementary Figure S6. AURKB expression correlates with HOXB13 in human CTCs from mCRPC patients following Abiraterone therapy; Supplementary Fig. S7. AURKB is a therapeutic vulnerability of HOXB13 positive prostate cancers
Figure S4 from The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth
Authors: Wang Yuhua , Pandey Ram Naresh , Riffle Stephen , Chintala Hemabindu , Wikenheiser-Brokamp Kathryn A. , Hegde Rashmi S.
Published: April 2023

Representative hematoxylin and eosin staining of vehicle and BZ treated LLC tumors.
Figure S5 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

Effects of pioglitazone on three breast cancer cell lines. A, MCF-7:2A cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 9 days. Cells were then harvested for use in an annexin V binding assay. *P<0.05, **P<0.001 compared with control. B, MCF-7:2A cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 9 days. Cells were then harvested in TRIzol reagent. HMOX1 expression levels were quantitated using RT-PCR. **P<0.001, compared with control. C, MCF-7 cells were transferred from phenol red containing medium to E2-free medium for 3 days. Cells were then seeded in 24-well plates. After 24 hours, cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 7 days. Cells were harvested for DNA growth assay. **P<0.001 compared with control. D, MCF-7:5C cells were seeded in 24-well plates. After 24 hours, cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 7 days. Cells were harvested for DNA growth assay. *P<0.05, **P<0.001 compared with control. E, MCF-7:2A cells were seeded in 24-well plates. After 24 hours, cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 7 days. Cells were harvested for DNA growth assay. *P<0.05, **P<0.001 compared with control. F, Effects on E2-induced IRE1α by pioglitazone in MCF-7:5C cells. MCF-7:5C cells were treated with E2 (1 nM), pioglitazone (10 µM), or a combination of them for 3 days. IRE1α expression was detected using Western blotting. G, Effects on E2-induced IRE1α by pioglitazone in MCF-7:2A cells. MCF-7:2A cells were treated with E2 (1 nM), pioglitazone (10 µM), or a combination of them for 9 days. IRE1α expression was detected using Western blotting.
Figure S1 from The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth
Authors: Wang Yuhua , Pandey Ram Naresh , Riffle Stephen , Chintala Hemabindu , Wikenheiser-Brokamp Kathryn A. , Hegde Rashmi S.
Published: April 2023

Tamoxifen-induced loss of EYA3 protein in the tumor vasculature of Eya3VEC-KO mice.
Supplementary Methods from A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
Authors: Miller Michael L. , Shizuka Manami , Wilhelm Alan , Salomon Paulin , Reid Emily E. , Lanieri Leanne , Sikka Surina , Maloney Erin K. , Harvey Lauren , Qiu Qifeng , Archer Katie E. , Bai Chen , Vitharana Dilrukshi , Harris Luke , Singh Rajeeva , Ponte Jose F. , Yoder Nicholas C. , Kovtun Yelena , Lai Katharine C. , Ab Olga , Pinkas Jan , Keating Thomas A. , Chari Ravi V.J.
Published: April 2023

Supplementary Methods
Supplementary Figures S1-S9 from A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
Authors: Miller Michael L. , Shizuka Manami , Wilhelm Alan , Salomon Paulin , Reid Emily E. , Lanieri Leanne , Sikka Surina , Maloney Erin K. , Harvey Lauren , Qiu Qifeng , Archer Katie E. , Bai Chen , Vitharana Dilrukshi , Harris Luke , Singh Rajeeva , Ponte Jose F. , Yoder Nicholas C. , Kovtun Yelena , Lai Katharine C. , Ab Olga , Pinkas Jan , Keating Thomas A. , Chari Ravi V.J.
Published: April 2023

Figure S1. Structural representations and scheme for preparation of IGN ADCs. Figure S2A. In vitro potency comparing ADCs of an IGN DNA cross-linker and DNA alkylator. Figure S2B. In vitro potency comparing ADCs of an IGN DNA cross-linker and DNA alkylator. Figure S3. Immunohistochemistry (IHC) assessment. Figure S4. In vivo antitumor activity comparing ADCs of an IGN DNA cross-linker and DNA alkylator. Figure S5. Single-dose ADC tolerability in CD-1 mice. Figure S6. Bystander killing assessment. Figure S7. Synthesis of a radiolabeled ADC. Figure S8. Identification of DNA adducted catabolites by LC/MS. Figure S9. Pharmacokinetic profiles.
Supplementary Fig 4 from Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling
Authors: Gupta Nehal , Srivastava Sanjay K.
Published: April 2023

Supplementary figure S4 shows the diagram depicting the mechanism of atovaquone (ATQ) in breast cancer cells
Supplementary Data Tables S1, S2, S3, and Figs. S1 and S2 from Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy
Authors: Saadat Nadia , Liu Fangchao , Haynes Brittany , Nangia-Makker Pratima , Bao Xun , Li Jing , Polin Lisa A. , Gupta Smiti , Mao Guangzhao , Shekhar Malathy P.
Published: April 2023

Contains Materials, Method of metabolite extraction and 1H-NMR analysis. Supplementary Table S1 shows size measurements of GNPs. Supplementary Table S2 shows summary of metabolic pathway analysis in SUM1315 triple negative breast cancer cells. Supplementary Table S3 shows summary of metabolic pathway analysis in MDA-MB-231 triple negative breast cancer cells. Supplementary Figure S1 shows PCA loading plots of SUM1315 and MDA-MB-231 cells treated with blank-GNP or SMI#9-GNP. Supplementary Figure S2 shows PLS-DA plots of SUM1315 and MDA-MB-231 cells treated with blank-GNP or SMI#9-GNP.
Supplementary Data from Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer
Authors: Todenhöfer Tilman , Seiler Roland , Stewart Craig , Moskalev Igor , Gao Jian , Ladhar Simroop , Kamjabi Alireza , Al Nakouzi Nader , Hayashi Tetsuharo , Choi Stephen , Wang Yuzhuo , Frees Sebastian , Daugaard Mads , Oo Htoo Zarni , Fisel Pascale , Schwab Matthias , Schaeffeler Elke , Douglas James , Hennenlotter Jörg , Bedke Jens , Gibb Ewan A. , Fazli Ladan , Stenzl Arnulf , Black Peter C.
Published: April 2023

Suppl. Table 1: Characteristics of the TCGA cohort; Suppl. Table 2: Characteristics of cohort A. CIS= carcinoma in situ; Suppl. Table 3: Characteristics of cohort B Suppl. Fig. 1. Correlation of degree of DNA methylation at CpG site cg10183885 in the SLC16A3 gene region (see Suppl. Table 4) and MCT4 mRNA expression; Suppl. Fig. 2. Correlation of gene expression and protein expression in cohort B. Suppl. Fig. 3. Representative H&E (upper panel) and immunohistochemical images in matched bladder cancer samples (each column is one patient). CD8 was used to stain T cells (middle panel) in comparison with MCT4 expression (lower panel). Suppl. Fig. 4. Protein expression of MCT4 in benign urothelium, primary tumor tissue and lymph node metastases (cohort A). Suppl. Fig. 5. Protein expression in primary tumors according to tumor stage (left) and lymph node involvement (right) (cohort A).; Suppl. Fig. 6. MCT4 mRNA expression correlates with molecular subtypes in the TCGA cohort using the updated TCGA nomenclature (n=408); Suppl. Fig. 7. MCT4 gene expression does not correlate with overall survival in a cohort of patients undergoing neoadjuvant chemotherapy; Suppl. Fig. 8. Expression of MCT4 in urothelial carcinoma cell lines detected by Western Blot (A) and qPCR (B); Suppl. Fig. 9. Effect of MCT4 silencing on cell growth in hypoxic conditions determined by MTT assay. Suppl. Fig. 10. Effect of inhibition of MCT4 using siRNA on cell growth of the MCT4 negative cell line RT4 determined by MTT assay; Suppl. Fig 11. Effect of MCT4 silencing on cell growth in glucose free conditions determined by MTT assay; Suppl.Fig. 12. Effect of different concentrations of MCT4 specific antisense olignucleotide (ASO) on cell growth determined by MTT assay. Suppl. Fig. 13. Oxygen consumption rates at baseline (A), following glucose injection (B) and following oligomycin injection (C) in cell lines treated with control siRNA or MCT4 specific siRNAs.
Movie S8 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in PIP3 treated HUVEC cells
Supplementary Table 1 from TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Authors: Ghosh Srimoyee , Sharma Geeta , Travers Jon , Kumar Sujatha , Choi Justin , Jun H. Toni , Kehry Marilyn , Ramaswamy Sridhar , Jenkins David
Published: April 2023

Comparison of mouse and humanized anti-PD-1 and anti-LAG-3 antibodies used in syngeneic and humanized mouse tumor models
Supplementary Fig 3 from TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Authors: Ghosh Srimoyee , Sharma Geeta , Travers Jon , Kumar Sujatha , Choi Justin , Jun H. Toni , Kehry Marilyn , Ramaswamy Sridhar , Jenkins David
Published: April 2023

Kaplan-Meier survival curves for huNOG-EXL mice implanted with A549 NSCLC cells treated with isotype control, TSR-042, TSR-033 or TSR-042+TSR-033
Supplement Figure 1 from Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Authors: Hu Jing , Zhang Huijuan , Cao Mengru , Wang Li , Wu Shuhong , Fang Bingliang
Published: April 2023

Dose-response curves of acalabrutinib in four NSCLC cell lines. H1975 and HCC827 cells are EGFR mutant while Calu3 and A549 are EGFR wild-type. Data are presented as the mean {plus minus} standard deviation (SD) of a quadruplet assay. Cells treated with DMSO alone were used as controls, and their values were set as 1. All four cell lines have IC50 > 3 μM for acalabrutinib.
Figure S5 Flow cytometry analysis of apoptosis upon PIP3 treatment. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Hela cells were treated with or without 10 μM PIP3 for 72 hours and then labeled by Propidium iodide and Annexin V-FITC for detecting early and late apoptotic signal.
Figure S3 Time-dependent cellular uptake of PIP3. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

(a) Hela cells or (b) A549 cells stably expressing histone H2B-RFP were incubated with 10 μM of PIP3. At different time points, cells were harvested, stained, and imaged. Scale bar, 50 μm. (c) Nuclear localization of PIP3 in A549 cells. Scale bar, 10 μm.
Figure s1 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

REGN2810 binds to PD-1 on engineered Jurkat cells and on activated human and cynomolgus monkey T cells.
Figure S3 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

Cytokine release following human PBMC exposure to immobilized REGN2810, REGN2329 (TGN1412) and anti-CD3 (OKT3) antibodies.
Supplementary Figure S5 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Suppl. Fig. 5 shows representative microscopic phase-contrast images of ADT-treated and untreated U87-MG-shp53 spheroids at defined times after transfer to different ECM-coated adherent surfaces.
Supplemental Table 1 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Mean growth delay values as calculated from the data documented in Suppl. Fig. 4B. The data listed here are also visualized in Fig. 4 and show that synergistic effects of ADT and irradiation are implicated at higher doses.
Supplementary Figure 4 from Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Authors: Eke Iris , Makinde Adeola Y. , Aryankalayil Molykutty J. , Sandfort Veit , Palayoor Sanjeewani T. , Rath Barbara H. , Liotta Lance , Pierobon Mariaelena , Petricoin Emanuel F. , Brown Matthew F. , Stommel Jayne M. , Ahmed Mansoor M. , Coleman C. Norman
Published: April 2023

Subcellular localization of AKT and mTOR after radiation. Immunofluorescence staining of AKT and mTOR in irradiated and unirradiated DU145 and PC3 cells. Nuclear staining was performed with DAPI.
Supplemental Matrerials & Methods from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Details on (i) the generation of the p53-knockdown cell line, (ii) 3-D spheroid culturing & handling, (iii) colony formation assay performance and (iv) the use of primary and secondary antibodies in Western blot analyses.
Supplementary Figure 2 from Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Authors: Eke Iris , Makinde Adeola Y. , Aryankalayil Molykutty J. , Sandfort Veit , Palayoor Sanjeewani T. , Rath Barbara H. , Liotta Lance , Pierobon Mariaelena , Petricoin Emanuel F. , Brown Matthew F. , Stommel Jayne M. , Ahmed Mansoor M. , Coleman C. Norman
Published: April 2023

Gene expression of mTOR/AKT related genes after single dose and multifractionated radiation. DU145 human prostate carcinoma cells were irradiated with 10 Gy single dose (SD) or 5 fractions of 2 Gy or 10 fractions of 1 Gy (2 Gy a day) as multifractionated (MF) radiotherapy. At indicated time points after radiation, cells were lysed and RNA was isolated.
Figure S1 from “Wnt/β-Catenin in GIST”—Letter
Authors: Bertucci François , Finetti Pascal , De Nonneville Alexandre , Birnbaum Daniel
Published: April 2023

β-catenin activation in GIST is associated with survival
Supplementary Figures 1-4 from NEO212 Inhibits Migration and Invasion of Glioma Stem Cells
Authors: Marín-Ramos Nagore I. , Thein Thu Zan , Cho Hee-Yeon , Swenson Stephen D. , Wang Weijun , Schönthal Axel H. , Chen Thomas C. , Hofman Florence M.
Published: April 2023

Supplementary Figure 1. NEO212 is a conjugate of POH and TMZ; Supplementary Figure 2. NEO212 impairs GSC migration without affecting cell viability; Supplementary Figure 3. NEO212 impairs the invasion of several primary cultures of GBM cells and GSCs; Supplementary Figure 4. NEO212 is not toxic at the doses used for in vivo treatments and is maintained longer in tumor-bearing brains as compared to normal brains.
Figure S5 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Authors: Su Zhipeng , Han Yunchun , Sun Qichen , Wang Xiaoxiao , Xu Ting , Xie Wei , Huang Xing
Published: April 2023

Figure S5 shows anti-MET VHH pool reducing cell surface-located MET.
Figure S3 from The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo
Authors: Wahba Amy , Rath Barbara H. , O'Neill John W. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

XPO1 expression in glioblastoma cell lines versus normal cell lines.
Supplementary Figures S1-6 from Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non–Small Cell Lung Cancer
Authors: Hirano Toshiyuki , Yasuda Hiroyuki , Hamamoto Junko , Nukaga Shigenari , Masuzawa Keita , Kawada Ichiro , Naoki Katsuhiko , Niimi Tatsuya , Mimasu Shinya , Sakagami Hideki , Soejima Kenzo , Betsuyaku Tomoko
Published: April 2023

Figure S1:Apoptosis induction by osimertinib and naquotinib in EGFR T790M positive mutations. Figure S2:Selectivity index of the EGFR-TKIs. Figure S3:Effects of EGFR-TKIs on EGFR downstream signals in Ba/F3 cells expressing different EGFR genotypes. Figure S4:Selectivity index of the EGFR-TKIs for indicated EGFR mutations. Figure S5:Inhibition of EGFR downstream signals by EGFR-TKIs in EGFR Y764_V765insHH. Figure S6:Structural model of A767_V769dupASV.
Supplementary Figure S1 from Leelamine Is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo
Authors: Singh Krishna B. , Hahm Eun-Ryeong , Pore Subrata K. , Singh Shivendra V.
Published: April 2023

Effect of leelamine (LLM) treatment on neutral lipid droplet accumulation in LNCaP and PC-3 prostate cancer cells and RWPE-1 normal prostate epithelial cell line.
Supplementary Figures S1-S13 and Supplementary Tables S1-S2 from Mechanistic Modeling of Antibody–Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps
Authors: Durbin Kenneth R. , Phipps Colin , Liao Xiaoli
Published: April 2023

Figure S1 - Ab033 EGFR binding kinetics. Figure S2 - Number of surface EGF receptors. Figure S3 - Workflow for internalization rate determination. Figure S4 - Comparison of Ab033 mAb and ADC internalization rates. Figure S5 - Visualization of internalization in H441 cells. Figure S6 - Visualization of full internalization time course in A431 cells. Figure S7 - Surface localization and internalization scores by imaging flow cytometry. Figure S8 - Quenching of AlexaFluor 488 fluorescence. Figure S9 - Colocalization of Ab033 to the lysosome. Figure S10 - Uptake and trafficking of Ab033 with pH sensitive dye. Figure S11 - Preparation of Ab033-E2/F2. Figure S12 - Drug concentration in media. Figure S13 - Mechanistic cellular model. Table S1 - Model equations. Table S2 - Model parameters.
Figure S5 from Cholesterol Depletion by TASIN-1 Induces Apoptotic Cell Death through the ER Stress/ROS/JNK Signaling in Colon Cancer Cells
Authors: Zhang Lu , Kim Sang Bum , Luitel Krishna , Shay Jerry W.
Published: April 2023

Supplementary Figure 5. TASIN-1 induces apoptosis in HCT116 cells expressing truncated APC.
Figures S1-S4, Tables S1-S2 from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
Authors: Bhakta Sunil , Crocker Lisa M. , Chen Yvonne , Hazen Meredith , Schutten Melissa M. , Li Dongwei , Kuijl Coenraad , Ohri Rachana , Zhong Fiona , Poon Kirsten A. , Go Mary Ann T. , Cheng Eric , Piskol Robert , Firestein Ron , Fourie-O'Donohue Aimee , Kozak Katherine R. , Raab Helga , Hongo Jo-Anne , Sampath Deepak , Dennis Mark S. , Scheller Richard H. , Polakis Paul , Junutula Jagath R.
Published: April 2023

Figure S1. Validation of anti-GFRA1 antibodies (R&D systems and GNE-8H6) for the use of Immunohistochemistry (IHC) analysis; Figure S2. ELISA analyses to test binding specificity of anti-GFRA1 antibodies to GFRA1 (A) and GFRA2 (B) extra cellular domain-Fc fusion proteins; Figure S3. Pharmacokinetics of anti-GFRA1 ADCs in tumor xenograft models; Figure S4. FACS of anti-GFRA1, hu-6D3.v5 (A) and hu-7C9 (B) antibody titration on HEK293-overexpressing human, cynomolgus monkey, rat and mouse GFRA1 cells showing similar binding; Table S1. Affinity characterization of anti-GFRA1 IgG antibodies on Immobilized hu- GFRA1Fc ligand; Table S2. Bioanalytical characterization of anti-GFRA1 ADCs.
Figure S4 from Cholesterol Depletion by TASIN-1 Induces Apoptotic Cell Death through the ER Stress/ROS/JNK Signaling in Colon Cancer Cells
Authors: Zhang Lu , Kim Sang Bum , Luitel Krishna , Shay Jerry W.
Published: April 2023

Supplementary Figure 4. TASIN-1 inhibits phosphorylation of mTOR in DLD1 cells.
Figure S1 from Cholesterol Depletion by TASIN-1 Induces Apoptotic Cell Death through the ER Stress/ROS/JNK Signaling in Colon Cancer Cells
Authors: Zhang Lu , Kim Sang Bum , Luitel Krishna , Shay Jerry W.
Published: April 2023

Supplementary Figure 1. Growth curves of HCT116 cells treated with DMSO or 2.5 µM of TASIN-1 continuously in HCEC media with 0.2% serum.
Figure S6 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks
Authors: Soni Aashish , Li Fanghua , Wang You , Grabos Martha , Krieger Lisa Marie , Chaudhary Shipra , Hasan Mohammad Sharif Mortoga , Ahmed Mansoor , Coleman C. Norman , Teicher Beverly A. , Piekarz Richard L. , Wang Dian , Iliakis George E.
Published: April 2023

(A) The DR-GFP reporter assay fails to detect an effect of BMN673. (B) BMN673 impairs DSB repair in human sarcoma and rhabdoid cell liines.
Figure S5 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks
Authors: Soni Aashish , Li Fanghua , Wang You , Grabos Martha , Krieger Lisa Marie , Chaudhary Shipra , Hasan Mohammad Sharif Mortoga , Ahmed Mansoor , Coleman C. Norman , Teicher Beverly A. , Piekarz Richard L. , Wang Dian , Iliakis George E.
Published: April 2023

IR induced Rad51 foci colocalize with gamma H2AX foci
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Authors: Gomes Bruno , Driessens Gregory , Bartlett Derek , Cai Danying , Cauwenberghs Sandra , Crosignani Stefano , Dalvie Deepak , Denies Sofie , Dillon Christopher P. , Fantin Valeria R. , Guo Jie , Letellier Marie-Claire , Li Wenlin , Maegley Karen , Marillier Reece , Miller Nichol , Pirson Romain , Rabolli Virginie , Ray Chad , Streiner Nicole , Torti Vince R. , Tsaparikos Konstantinos , Van den Eynde Benoit J. , Wythes Martin , Yao Li-Chin , Zheng Xianxian , Tumang Joseph , Kraus Manfred
Published: April 2023

Table S1 shows the plasma protein binding and blood to plasma ratio in mouse, rat, dog and human. Table S3 shows the plasma concentrations following a single oral dose of PF-06840003. Figure S1 shows that PF-06840003 does not impact cell viability. Figure S2 shows that PF-06840003 rescues T-cell proliferation in a co-culture assay. Figure S3 shows tumor growth inhibition of CT26 tumors at different dose levels. Figure S4 shows that IDO1 inhibitor mediated tumor growth inhibition depends on CD8+ T cells. Figure S5 shows a combination benefit with anti-PD-L1 treatment in CT26 tumors. Figure S6 shows IDO1i mediated tumor growth inhibition of MDA-MB-231 breast tumors in humanized mice. Figure S7 shows that PF-06840003 improves the TGI of avelumab in a humanized mouse breast tumor model. Figure S8 shows the fractions of CT26 tumor immune infiltrating cells.
Supplementary Figure 2 from Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor
Authors: Bhatia Shilpa , Griego Anastacia , Lennon Shelby , Oweida Ayman , Sharma Jaspreet , Rohmer Christina , Uyanga Nomin , Bukkapatnam Sanjana , Van Court Benjamin , Raben David , Young Christian , Heasley Lynn , Karam Sana D.
Published: April 2023

EphB3 and PI3 Kinase p110α are variably expressed in human HNSCC cells.
Supplemental Tables S1-3 from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance
Authors: Quanz Maria , Bender Eckhard , Kopitz Charlotte , Grünewald Sylvia , Schlicker Andreas , Schwede Wolfgang , Eheim Ashley , Toschi Luisella , Neuhaus Roland , Richter Carmen , Toedling Joern , Merz Claudia , Lesche Ralf , Kamburov Atanas , Siebeneicher Holger , Bauser Marcus , Hägebarth Andrea
Published: April 2023

Supplemental Table S1: Selectivity profile of BAY-8002. Supplemental Table S2: Summary table of functional and proliferation IC50 data for BAY-8002 and AZD3965. Supplemental Table S3: Responses to BAY-8002 and AZD3965 of cell lines with acquired resistance to MCT1 inhibition.
Figures S1-S5 from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance
Authors: Quanz Maria , Bender Eckhard , Kopitz Charlotte , Grünewald Sylvia , Schlicker Andreas , Schwede Wolfgang , Eheim Ashley , Toschi Luisella , Neuhaus Roland , Richter Carmen , Toedling Joern , Merz Claudia , Lesche Ralf , Kamburov Atanas , Siebeneicher Holger , Bauser Marcus , Hägebarth Andrea
Published: April 2023

Supplemental Figure S1: A, SLC16A1 (MCT1), SLC16A7 (MCT2), SLC16A8 (MCT3) and SLC16A3 (MCT4) mRNA expression levels and Effects of BAY-8002 on lactate Export and ECAR. Supplemental Figure S2: Binding affinity of the two MCT1 inhibitors BAY-8002 and AZD3965. Supplemental Figure S3: supplemental cell panel analysis. Supplemental Figure S4: subset analysis of MCT4 low expressing cells from the cell panel Analysis. Supplemental Figure S5: Intratumor 2/3-PG and 6PG levels after treatment with AZD3965
Figure S1 from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Authors: Phillips Andrew C. , Boghaert Erwin R. , Vaidya Kedar S. , Falls Hugh D. , Mitten Michael J. , DeVries Peter J. , Benatuil Lorenzo , Hsieh Chung-Ming , Meulbroek Jonathan A. , Panchal Sanjay C. , Buchanan Fritz G. , Durbin Kenneth R. , Voorbach Martin J. , Reuter David R. , Mudd Sarah R. , Loberg Lise I. , Ralston Sherry L. , Cao Diana , Gan Hui K. , Scott Andrew M. , Reilly Edward B.
Published: April 2023

Amino Acid Sequence of AM-1 VH Region
Supplementary Figure legends and methods from Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies
Authors: Didier Robin , Mallavialle Aude , Ben Jouira Rania , Domdom Marie Angela , Tichet Mélanie , Auberger Patrick , Luciano Frédéric , Ohanna Mickael , Tartare-Deckert Sophie , Deckert Marcel
Published: April 2023

Supplementary Figure legends and methods
Table S2 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

IC50 values (µM) of 6-thio-dG treatment for 7 days in the cell lines used.
Figure S3 from Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models
Authors: Awasthi Niranjan , Schwarz Margaret A. , Zhang Changhua , Schwarz Roderich E.
Published: April 2023

Antiangiogenic agents and nab-paclitaxel: In vitro cell viability assays were performed using endothelial cell (HUVECs) and fibroblast (WI-38). WST-1 reagent was added after 72-hour treatment incubation and the absorbance was measured at 450 nm using a microplate reader.
Figure S2 from MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma
Authors: Dasgupta Pritha , Kulkarni Priyanka , Majid Shahana , Shahryari Varahram , Hashimoto Yutaka , Bhat Nadeem S. , Shiina Marisa , Deng Guoren , Saini Sharanjot , Tabatabai Z. Laura , Yamamura Soichiro , Tanaka Yuichiro , Dahiya Rajvir
Published: April 2023

Attenuation of HOTAIR promotes upregulation of PTEN, p21 and p27
Figure S1-S4 from Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer
Authors: Dey Anindya , Xiong Xunhao , Crim Aleia , Dwivedi Shailendra Kumar Dhar , Mustafi Soumyajit Banerjee , Mukherjee Priyabrata , Cao Liangxian , Sydorenko Nadiya , Baiazitov Ramil , Moon Young-Choon , Dumble Melissa , Davis Thomas , Bhattacharya Resham
Published: April 2023

Figure S1: Synthesis of PTC-028; Figure S2: Specificity of PTC-028 towards high BMI-1 expressing cells; Figure S3: PTC-028 induces caspase-dependent apoptosis; Figure S4: Pharmacokinetics of PTC-028 after a single oral dose of either 10 mg/kg or 20mg/kg to CD-1 mice
Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Authors: Shimizu Toshihiko , Ishida Joji , Kurozumi Kazuhiko , Ichikawa Tomotsugu , Otani Yoshihiro , Oka Tetsuo , Tomita Yusuke , Hattori Yasuhiko , Uneda Atsuhito , Matsumoto Yuji , Date Isao
Published: April 2023

Bevacizumab treatment led to increase in invasive and high expression of Î'-catenin. Silencing of Î'-catenin decreased bevacizumab-induced glioma invasion and Î'-catenin expression. Overexpressed Î'-catenin tumor cells showed more invasiveness and expressed high level ofÎ'-catenin protein in the tumor area in vivo.
Supplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Authors: Shimizu Toshihiko , Ishida Joji , Kurozumi Kazuhiko , Ichikawa Tomotsugu , Otani Yoshihiro , Oka Tetsuo , Tomita Yusuke , Hattori Yasuhiko , Uneda Atsuhito , Matsumoto Yuji , Date Isao
Published: April 2023

Bevacizumab increased the rate of wound closure
Figure S6 and S7 from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Figure S6 describes genomic analysis of resistant NCI-H2077 cells and Figure S7 shows weight of animals of xenograft studies.
Figure S5 from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Figure S5 shows morphologic characterization and expression patterns of FGFR-inhibitor resistant clones
Supplementary Figure 3 from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Brownstein Jeremy M. , Wisdom Amy J. , Castle Katherine D. , Mowery Yvonne M. , Guida Peter , Lee Chang-Lung , Tommasino Francesco , Tessa Chiara La , Scifoni Emanuele , Gao Junheng , Luo Lixia , Campos Lorraine Da Silva , Ma Yan , Williams Nerissa , Jung Sin-Ho , Durante Marco , Kirsch David G.
Published: April 2023

Quantification of TUNEL staining for sarcomas at 24 or 48 hours after 10 Gy carbon ions or 30 Gy X-rays. A) TUNEL staining was similar, indicating that there were no significant differences in cell death. B) TUNEL staining at 24 and 48 hours.
Figure S1 from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Figure S1 shows sensitivity of NCI-H2077 cells to FGFR inhibition
Supplementary Figure 1 from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Brownstein Jeremy M. , Wisdom Amy J. , Castle Katherine D. , Mowery Yvonne M. , Guida Peter , Lee Chang-Lung , Tommasino Francesco , Tessa Chiara La , Scifoni Emanuele , Gao Junheng , Luo Lixia , Campos Lorraine Da Silva , Ma Yan , Williams Nerissa , Jung Sin-Ho , Durante Marco , Kirsch David G.
Published: April 2023

Comparing the effect anesthetic agent and housing location on tumor quintupling. A) Tumor quintupling times in mice treated with 20 Gy X-rays who were anesthetized with ketamine/xylazine vs. isoflurane, demonstrating no significant differences. B) Tumor quintupling time in untreated controls followed at Brookhaven National Laboratory vs. Duke University Medical Center, demonstrating no significant differences.
Supplementary Figure S2 from Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering
Authors: Kaplan Gilad , Mazor Ronit , Lee Fred , Jang Youjin , Leshem Yasmin , Pastan Ira
Published: April 2023

Production and screening of ZZ-PE mutant fusion proteins
Supplementary Table 1 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Authors: Iavarone Claudia , Zervantonakis Ioannis K. , Selfors Laura M. , Palakurthi Sangeetha , Liu Joyce F. , Drapkin Ronny , Matulonis Ursula A. , Hallberg Dorothy , Velculescu Victor E. , Leverson Joel D. , Sampath Deepak , Mills Gordon B. , Brugge Joan S.
Published: April 2023

Supplementary Table 1 shows the p53 mutation in the PDX models
Figure S7 from Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Puente-Moncada Noelia , Costales Paula , Antolín Isaac , Núñez Luz-Elena , Oro Patricia , Hermosilla Maria Ana , Pérez-Escuredo Jhudit , Ríos-Lombardía Nicolás , Sanchez-Sanchez Ana M. , Luño Elisa , Rodríguez Carmen , Martín Vanesa , Morís Francisco
Published: April 2023

MOLM-16 xenograft
Supplemental Figure 1 from STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer
Authors: Njatcha Christian , Farooqui Mariya , Kornberg Adam , Johnson Daniel E. , Grandis Jennifer R. , Siegfried Jill M.
Published: April 2023

Localization of Fluorecein-labeled CS3D by confocal Imaging
Figure S5 from Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Puente-Moncada Noelia , Costales Paula , Antolín Isaac , Núñez Luz-Elena , Oro Patricia , Hermosilla Maria Ana , Pérez-Escuredo Jhudit , Ríos-Lombardía Nicolás , Sanchez-Sanchez Ana M. , Luño Elisa , Rodríguez Carmen , Martín Vanesa , Morís Francisco
Published: April 2023

Mice weight during the xenograft experiments
Figure S2 from Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Puente-Moncada Noelia , Costales Paula , Antolín Isaac , Núñez Luz-Elena , Oro Patricia , Hermosilla Maria Ana , Pérez-Escuredo Jhudit , Ríos-Lombardía Nicolás , Sanchez-Sanchez Ana M. , Luño Elisa , Rodríguez Carmen , Martín Vanesa , Morís Francisco
Published: April 2023

Effect of SGI-1776 in AML cells
Supplementary Table S1 from Targeting MEK in a Translational Model of Histiocytic Sarcoma
Authors: Takada Marilia , Hix Jeremy M.L. , Corner Sarah , Schall Peter Z. , Kiupel Matti , Yuzbasiyan-Gurkan Vilma
Published: April 2023

Immunohistochemical characterization of histiocytic diseases in humans and dogs
Supplementary Figure S2 from Targeting MEK in a Translational Model of Histiocytic Sarcoma
Authors: Takada Marilia , Hix Jeremy M.L. , Corner Sarah , Schall Peter Z. , Kiupel Matti , Yuzbasiyan-Gurkan Vilma
Published: April 2023

Images of metastatic sites of the HS xenograft mice
Supplementary Table S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Authors: Anderhub Simon J. , Mak Grace Wing-Yan , Gurden Mark D. , Faisal Amir , Drosopoulos Konstantinos , Walsh Katie , Woodward Hannah L. , Innocenti Paolo , Westwood Isaac M. , Naud Sébastien , Hayes Angela , Theofani Efthymia , Filosto Simone , Saville Harry , Burke Rosemary , van Montfort Rob L.M. , Raynaud Florence I. , Blagg Julian , Hoelder Swen , Eccles Suzanne A. , Linardopoulos Spiros
Published: April 2023

TNBC and non-TNBC cell line subtype, cell cycle and SAC characteristics and BOS172722 potency.
Supplementary Figure S4 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Authors: Anderhub Simon J. , Mak Grace Wing-Yan , Gurden Mark D. , Faisal Amir , Drosopoulos Konstantinos , Walsh Katie , Woodward Hannah L. , Innocenti Paolo , Westwood Isaac M. , Naud Sébastien , Hayes Angela , Theofani Efthymia , Filosto Simone , Saville Harry , Burke Rosemary , van Montfort Rob L.M. , Raynaud Florence I. , Blagg Julian , Hoelder Swen , Eccles Suzanne A. , Linardopoulos Spiros
Published: April 2023

Chromosome alignment errors, time course and synergy volume in cells treated with BOS172722 and Paclitaxel.